MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level and are important for coordinating nervous system development and neuronal function in the mature brain. We have recently identified schizophrenia-associated alteration of cortical miRNA biogenesis and expression in post-mortem brain tissue with implications for the dysregulation of schizophrenia candidate genes. Although these changes were observed in the central nervous system, it is plausible that schizophrenia-associated miRNA expression signatures may also be detected in non-neural tissue. To explore this possibility, we investigated the miRNA expression profile of peripheral blood mononuclear cells (PBMCs) from 112 patients with schizophrenia and 76 non-psychiatric controls. miRNA expression analysis of total RNA conducted using commercial miRNA arrays revealed that 33 miRNAs were significantly downregulated after correction for multiple testing with a false discovery rate (FDR) of 0%, which increased to 83 when we considered miRNA with an FDR < 5%. Seven miRNAs altered in microarray analysis of schizophrenia were also confirmed to be downregulated by quantitative real-time reverse transcription-polymerase chain reaction. A large subgroup consisting of 17 downregulated miRNAs is transcribed from a single imprinted locus at the maternally expressed DLK1-DIO3 region on chromosome 14q32. This pattern of differentially expressed miRNA in PBMCs may be indicative of significant underlying genetic or epigenetic alteration associated with schizophrenia.
Introduction
Schizophrenia is a severely debilitating and complex neuropsychiatric disorder afflicting nearly one in 100 people throughout life. 1 Although some gross neuroanatomical and histological features have been associated with schizophrenia, none are consistent enough to be considered diagnostic. [2] [3] [4] [5] [6] [7] The scarcity of tangible pathology means that clinical diagnosis is based on descriptive criteria and requires persistent or episodic presence of certain symptoms over a defined period with associated disability and exclusion of other psychiatric conditions. As early intervention in schizophrenia is thought to be important in improving outcome, any delay in diagnosis or misdiagnosis owing to the inherent limitations of clinical descriptors may have a negative prognostic impact. 8, 9 Consequently, accessible biological markers are needed to improve the timing and accuracy of diagnosis, and identify individuals at very high risk of schizophrenia. This information may also provide the opportunity to tailor treatment to the individual and enable more effective early intervention. [10] [11] [12] [13] Despite having a strong genetic component, early expectations of a simple genetic diagnostic for schizophrenia have been thwarted as the heritability appears to involve a complex, heterogeneous mixture of common variants, each with small effect size. 14 More recently, studies have attempted to move closer to the neuropathology of schizophrenia in an attempt to identify common pathways in the disorder. High-throughput gene expression analysis has revealed altered gene expression in post-mortem brain including the dorsolateral prefrontal cortex, superior temporal gyrus and amygdala, which are all functionally relevant to the pathology of schizophrenia. [15] [16] [17] [18] [19] [20] [21] [22] Although no single gene has been found to be consistently altered across studies or brain regions, most report the enrichment of pathways relevant to the putative neurobiology of schizophrenia. In many instances, the extent and shape of gene alteration in post-mortem brain may imply the involvement of aberrant regulatory or epigenetic influences. In support of this hypothesis, we recently reported changes in cortical microRNA (miRNA) biogenesis and expression in schizophrenia. 23, 24 These molecules strongly influence gene expression, particularly in the brain where they are thought to be involved in both neurodevelopment and in the regulation of synaptic structure and function. [25] [26] [27] [28] [29] Although the pathophysiology of changes in cortical miRNA expression remains to be determined, it is plausible that alteration of miRNA expression extends beyond the brain and could provide useful peripheral biomarkers for schizophrenia that would be accessible for clinical use. miRNA molecules are highly stable 30 and, owing to their regulatory function (predicted to regulate half of the human genome 31 ), are arguably more informative and prognostic than gene expression. Certainly in the field of cancer biology, miRNA may be a more accurate predictor of tumor phenotype than its genotype. 32, 33 miRNA profiling of tissues and body fluids has been instructive in a variety of cancer types including chronic lymphocytic leukemia and lung, prostate, bladder and breast cancer. [34] [35] [36] [37] Perhaps more relevant to brain disorders like schizophrenia, miRNA profiling of whole blood in multiple sclerosis has revealed expression signatures associated with the disease and its remission status. 38 Similarly, miRNA analysis in Alzheimer's disease has revealed significant patterns of altered expression in peripheral blood mononuclear cells (PBMCs) 39 as well as in the cerebrospinal fluid and brain. 40 PBMCs in particular represent an attractive alternative tissue for profiling active disease in living patients at statistically robust numbers. This accessible tissue can reflect global disease-associated changes in an underlying genetic disorder and may have special significance where immunological risk factors are believed to be involved. In schizophrenia, for example, prenatal maternal infection is thought to be an important risk factor [41] [42] [43] [44] that may leave immunologically relevant expression signatures in PBMCs.
In this study, we examined miRNA expression in PBMCs derived from a cohort of schizophrenia patients and non-psychiatric controls, and identified a significant schizophrenia-associated reduction in 83 miRNAs. A large proportion of this expression signature was derived from a cluster of 17 miRNAs residing in a single imprinted domain on 14q32. This discovery has implications for our understanding of epigenetic regulation and inheritance in schizophrenia, and may also have applications as a novel biomarker for the disorder.
Materials and methods
Participant recruitment and clinical assessment protocol Participants, the majority of whom identified as Caucasian, were recruited by the Australian Schizophrenia Research Bank and the Hunter DNA Bank. In this study, the cohorts consisted of 112 participants with a lifetime diagnosis of schizophrenia and 76 non-psychiatric controls that were deemed eligible for inclusion after assessment by qualified psychologists using the Diagnostic Interview for Psychosis. 45 Participants were excluded if they were currently diagnosed with any organic brain disorders, substance dependence, brain injury that caused posttraumatic amnesia lasting > 24 h, mental retardation (IQ < 70), movement disorder or if they had electroconvulsive therapy within 6 months. These exclusion criteria were likewise used for non-psychiatric control subjects with the additional criterion that they had no personal or family history of either psychosis or bipolar disorder type 1. 46 In addition, participants were required to speak English, and were aged between 18 and 65 years. Participants gave informed consent for inclusion in the study protocol, as approved by the institutional research ethics committees. All cases reported using antipsychotic medication at the time of interview and blood draw. Demographic and clinical variables of the cohort are summarized in Table 1 and described in detail in Supplementary Table 1 .
Extraction of RNA and DNA from whole blood Whole blood (20 ml) was collected from subjects and transported to the Australian Schizophrenia Research Bank for processing. PBMCs were extracted by centrifugation using Lymphoprep (Vital Diagnostics, Lincoln, RI, USA). Total RNA was extracted from PBMCs obtained using Trizol, as per the manufacturer's instructions (Invitrogen, Life Technologies, Carlsbad, CA, USA). RNA concentration was determined using a NanoDrop 2000 (Thermo Scientific, Delaware, ME, USA). Genomic DNA was extracted miRNA expression profiling Profiling of human miRNA expression (miRBase version 9.1) was achieved using the commercial miRNA microarray platform (Illumina, San Diego, CA, USA) as described previously. 47 Microarray data was extracted and normalized with respect to the geometric mean of U44 and U49 small nucleolar RNA (snoRNA) expression. Analysis of variance was used for the evaluation of association between non-diagnosis variance (batch effects, gender and age) and miRNA expression. Age showed a significant correlation with miRNA expression and was therefore used as a covariate in the subsequent analysis. Differential expression analysis was performed using the significance analysis of microarray statistical analysis program (full academic version 2.23, website http://www-stat.stanford.edu/ tibs/SAM/). 48 Normalized expression data for the differentially expressed miRNA is shown in Supplementary Table 2 . Unsupervised hierarchical clustering was performed in Cluster (Stanford University, Palo Alto, CA, USA; Eisen et al 49 ) and a heat map visualized through Java Treeview V.1.1.1. 50 Data were log transformed and median centered by genes. Genes and arrays were clustered, correlation un-centered, by average linkage clustering.
Quantitative real-time reverse transcription PCR Validation of differentially expressed miRNA was performed by quantitative real-time reverse transcription PCR on a subset of the cohort consisting of 91 participants (57 schizophrenia, 34 non-psychiatric controls), similarly to that described previously. 24 Briefly, 500 ng of sample RNA was treated with DNAse-I (Invitrogen, Life Technologies) and multiplex reverse transcription performed with Superscript II reverse transcriptase (Invitrogen, Life Technologies), a 3 nM mix of miRNA sequence-specific primers and primers for U44 snRNA and U49 snoRNA (for primer sequences, see Supplementary Table 3) . Seven miRNA were chosen for real-time validation on the basis of strong differential expression on the microarray and/or biological significance. Triplicate reactions were set up in a 96-well format using the epMotion 5070 automated pipetting system (Eppendorf, Hamburg, Germany) and carried out using the Applied Biosystems 7500 real-time PCR machine. Relative miRNA expression was determined with respect to the geometric mean of U44 and U49 snoRNAs by calculating the difference between the average cycle threshold (C t ) of the miRNA of interest and the geometric mean of the average C t values of housekeeping snoRNA for each sample (DC t ). Data were not normally distributed (as determined by GraphPad Prism version 5.0); therefore, the significance of differential expression was determined using a Mann-Whitney U-test (PASW Statistics 18).
Target prediction and functional pathway analysis
Putative target genes for schizophrenia-associated miRNA identified in this study were predicted using the miRanda 51 and TargetScan (release 5.1) 52 search algorithms (http://www.microrna.org/microrna/home.do; http://www.targetscan.org/). These putative target genes were further filtered by selecting genes containing five or more predicted binding sites either by the same or multiple miRNA as these genes are most likely to be regulated by the differentially expressed miRNA. 53 Pathway analysis was then performed on a combined list of targets from both algorithms (union), followed by a more stringent pathways analysis on those targets that were common to both miRanda and TargetScan (intersection) using WebGestalt Gene Set Analysis Toolkit V.2 (http://bioinfo.vanderbilt.edu/webgestalt/). 54 Visualization of pathways and networks from this information was facilitated by the construction of an 'enrichment map' of significant pathways (P < 0.05 Benjamini-Hochberg) containing seven or more genes per category (http://baderlab.org/Software/EnrichmentMap). 55 Analysis of copy-number variation Genomic copy-number status of the 14q32 region was investigated using commercial TaqMan copy-number assays (Applied Biosystems, Life Technologies, Carlsbad, CA, USA; Hs07397776_cn, Hs03879584_cn and Hs03889902_cn) corresponding to cytobands 14q32.2b, 14q32.2b and 14q32.31a, respectively (refer to Supplementary Figure 1 for details). Reactions were prepared as per the manufacturer's instructions using an EPMotion 5070 automated liquid handling device (Eppendorf) and carried out using an ABI7500 real-time PCR machine (Applied Biosystems). The CopyCaller software V.1.0 (Applied Biosystems) was used to calculate relative copy number at each of the three locations. Each sample was normalized to the copy-number reference assay (RNase P, part number 4 316 831), known to be present in two copies in a diploid genome.
Results miRNA expression analysis miRNA expression was analyzed in PBMCs of 112 patients with schizophrenia and 76 non-psychiatric controls using human miRNA array matrices (Illumina). After normalization and background subtraction, signals corresponding to 358 miRNAs or approximately 40% of the array content remained. Statistical analysis revealed 33 significantly downregulated miRNA at a false discovery rate (FDR) of 0% ( Figure 1a) increasing to 83 at an FDR < 5% (Table 2) . This included a number of brain-enriched miRNAs, miR-134, miR-128 and miR-181b. By contrast, there were no miRNAs that were significantly increased according to these criteria. Seven of the differentially expressed miRNA were further analyzed by quantitative real-time reverse transcription PCR in a representative sample consisting of 57 schizophrenia cases and 34 controls. miRNA expression was normalized to the geometric mean of two constitutively expressed snoRNAs U44 and U49. These results were highly concordant with the microarray analysis with all seven of the miRNAs confirmed to be significantly downregulated in schizophrenia compared with controls ( Figure 1b ) (two-tailed Mann-Whitney U-test). These included miR-31 (2.97-fold, P < 0.001), miR-431 (2.79-fold, P < 0.001), miR-433 (2.06-fold, P = 0.017), miR-107 (2.25-fold, P < 0.001), miR-134 (1.89-fold, P = 0.007), miR-99b (4.24-fold, P < 0.001) and miR487b (2.06-fold, P < 0.001).
Cluster analysis of schizophrenia-associated miRNA The miRNAs shown to be associated with schizophrenia in the microarray analysis were also subjected to hierarchical clustering ( Figure 2 ). This segregated the participants into two main groups in which reduced expression was enriched within the schizophrenia cohort ( Figure 2 , left side) in contrast to the majority of controls, which were visually distinguished by their relatively higher expression ( Figure 2 , right side). Strikingly, a cluster of 17 of the most substantially downregulated miRNAs were also structurally associated by their genomic position on the long arm of chromosome 14 (14q32). These miRNA all reside within two closely neighboring segments each spanning about 40 kb and separated by B110 kb, at 14q32.2 and 14q32.31 ( Figure 3 ). This cluster encodes at least 48 miRNA genes, 56, 57 of which 30 mature miRNAs were expressed in the PBMCs. This indicated that approximately 53% of the miRNAs expressed at this locus were significantly downregulated in schizophrenia. Moreover, when we examined miRNAs expressed in this cluster that were not significantly altered after correction for multiple testing, a further 10 miRNAs or 33% (including miR-493*, miR-665, miR-379, miR-411, miR-376a, miR-376b, miR-376c, miR-495, miR-539, miR-889) also displayed an average reduction in schizophrenia consistent with the trend seen in the majority of miRNAs expressed from this region. This pattern of expression among the clustered miRNAs associated with schizophrenia was also highly consistent within individuals, suggesting that their transcription may be under the influence of shared regulatory mechanisms.
Copy-number analysis
To investigate whether the downregulation of miRNA on chromosome 14q32.31-32.2 is related to structural variation, we analyzed a subset of samples including 57 controls and 81 cases using commercially available TaqMan copy-number assays (Applied Biosystems). Amplicons specific for sequence within maternally expressed gene 3, cluster A and cluster B of the 14q32 region, were analyzed relative to the endogenous control RNase-P. No significant deletion or amplification events were detected in this region in either cases or controls (Supplementary Figure 1) .
Target gene and pathway analysis
To gain some appreciation of the biological implications of the schizophrenia-associated changes in miRNA expression, we examined predicted miRNA targets and their associated pathways to see whether any patterns emerged. The more miRNA binding sites a gene has within its 3 0 -untranslated region, the more likely it is to be post-transcriptionally regulated. 53 The target prediction algorithms miRanda 51 and TargetScan 52 are capable of identifying those miRNA . The control cohort is set at 1. *P < 0.05; **P < 0.01; ***P < 0.001 by Mann-Whitney U-test.
Imprinted DLK1-DIO3 miRNA signature in schizophrenia E Gardiner et al Imprinted DLK1-DIO3 miRNA signature in schizophrenia E Gardiner et al Imprinted DLK1-DIO3 miRNA signature in schizophrenia E Gardiner et al that bind multiple times within the one 3 0 -untranslated region. As such, this information was used to predict target genes that were most likely to be heavily regulated by the differentially expressed miRNA. Owing to a high degree of false positives, the list of target genes was filtered to only include those genes that were targeted by five or more miRNA, or contained five or more binding sites for a particular miRNA within its 3 0 -untranslated region. This target analysis process was performed on the 17 miRNA displaying altered expression in the 14q32 region. The miRanda and TargetScan lists were then combined to form a union of targets predicted by both algorithms in addition to a more stringent analysis involving the intersection of targets identified by both miRanda and TargetScan. Selected genes were then collectively subjected to pathway analysis using the Gene Set Analysis Toolkit V.2 from WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt). 54 The union of miRanda and TargetScan revealed a number of significantly enriched pathways with relevance to neural connectivity and synaptic plasticity, including axon guidance, long-term potentiation, focal adhesion, neurotrophin, ErbB, calcium and mitogenactivated protein kinase signaling (Table 3 and Supplementary Figure 2) . Furthermore, the more stringent intersection approach, using genes predicted to be targets by both algorithms, also suggested the involvement of neurologically relevant pathways as well as pathways relevant to immune system function (Table 4 and Supplementary Figure 3) .
Discussion
A subset of brain-enriched miRNA genes located within a large imprinted cluster on chromosome 14q32 were differentially expressed in schizophrenia Analysis of post-mortem miRNA expression has previously reported schizophrenia-associated changes in both the superior temporal gyrus and prefrontal cortex. 24, 47, 58 Although miRNA expression typically displays a stage-and tissue-specific expression pattern, we identified several brain-enriched miRNAs including miR-134, miR-128 and miR-181b that were also differentially expressed in PBMCs from individuals with schizophrenia. It is plausible that these represent a neurologically relevant signature reflecting the prevailing neuropsychiatric phenotype. The reduction of miR-134 was particularly significant not only because of its role in brain development and function, 28, 59, 60 but also as a consequence of its position in a cluster of differentially expressed miRNAs on chromosome 14q32.
A large proportion of the miRNAs found to be differentially expressed in schizophrenia are encoded within this large cluster on chromosome 14q32, which collectively comprises over 5% of known human miRNA genes [61] [62] [63] and about 40-50% of all known eutherian-specific miRNA. 64 Significantly, this locus on 14q32, known as the DLK1-DIO3 region, is imprinted such that the associated miRNA cluster is only expressed from the maternal chromosome. 64 In mice, the syntenic region on chromosome 12 also resides within an imprinted domain expressed exclusively from the maternal chromosome. 57 The miRNAs are encoded by two clusters located in close proximity to each other, the smaller of the two at 14q32.2 contains 10 miRNA, which reside within the retrotransposon-like gene RTL1 (in antisense), whereas the larger cluster also known as the miR379-410 cluster contains approximately 40 miRNAs. Although the nature of their organization is not entirely clear in human beings, some of the miRNA in this region could be processed from a single large polycistron such as Mirg (miRNA containing gene, also known as Meg9), which appears to be the case in the mouse. However, it seems more likely that the majority of miRNA in this cluster are encoded by tandem arrays of related intronic sequences. 57, 65 Regulation of the 14q32 miRNA cluster As more than 85% of the miRNAs expressed in this region showed a trend for downregulation in schizophrenia, it is reasonable to suggest that these molecules may be co-regulated by a shared mechanism associated with the disorder. This could relate to a number of common factors that affect transcriptional activity or miRNA processing in this region. Why the remaining miRNAs expressed from this cluster were neutral with respect to disease status remains to be determined, but it could be that the genes encoding these molecules are responding more to differences in their local transcriptional environment, which over-ride the prevailing cluster-wide influence. They may also display isolated differences in their splicing or primary transcript processing, Abbreviations: HCM, hypertrophic cardiomyopathy; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogenactivated protein kinase; mTOR, mammalian target of rapamycin; TGF, tumor growth factor. Enriched KEGG pathways identified by WebGestalt gene set analysis using predicted target genes. The list was compiled from an union of the miRanda and TargetScan predicted targets of 17 members of the miR-14q32 cluster differentially expressed in schizophrenia. n, number of input genes in pathway (filtered to only show pathways represented by X7 target genes). %, percentage of total target genes analyzed (B3600 gene IDs) that are represented in this pathway. or pre-miRNA cleavage and maturation. It is also possible that the schizophrenia-associated regulatory influence seen for most of the expressed miRNA extends beyond the miRNA clusters to affect protein coding and other non-coding mRNAs in the region; however, there are no reports to this effect in the schizophrenia literature. A genome-wide study of MS from our laboratory suggests that the proteincoding genes in this domain (DLK1, RTL1, DIO3 and MEG3) are not expressed in lymphocytes. 66 Studies in the mouse suggest that the expression of miRNA clustered on 14q32 in human beings may be particularly sensitive to changes in the miRNA biogenesis pathway. For example, DiGeorge syndrome critical region gene 8 (DGCR8) heterozygous knockout mice were shown to have significantly reduced levels of mature miRNA expression from the syntenic region on chromosome 12 in both the prefrontal cortex and hippocampus. 67 The product of this gene, one of many depleted in the 22q11 microdeletion syndromes, is an important component of the microprocessor complex involved in pri-miRNA cleavage in the nucleus. Interestingly, these miRNA were also over represented (B25%) among miRNA showing downregulation in dopaminergic neurons from the striatum of Ago2-deficient mice. 68 A large proportion of miRNA from this cluster also contain primary and secondary structural features associated with dicerindependent/Ago2-slicer activity-dependent processing. 69 This includes the preponderance for an A/U base at the 5 0 terminal in the mature sequence (80%) and the preference for miRNA residing in the 3p side of precursor hairpins (B70%). 68, 70 This suggested that Ago2-dependent pre-miRNA processing 69, 71 is particularly important for the biogenesis of miRNA in this cluster and may be associated with changes we observed in schizophrenia. Another possibility is that a 14q32 cluster-associated transcription factor or other regulatory molecule is responsible for the change observed in schizophrenia. One example of this is the Ca 2 þ -activated transcription factor known as myocyte enhancer factor-2 (MEF2), which has been shown to positively regulate expression of miRNA in this cluster.
56 MEF2 isoforms have also been shown to regulate neuronal development through their role in supporting newly differentiated neurons and synapse formation. [72] [73] [74] [75] [76] We have also shown that expression of the MEF2D isoform is upregulated in differentiating neurons in response to a reduction in miR-17 family miRNA expression. 77 Lower expression of MEF2 in PBMC could potentially contribute to the reduction in transcription of this cluster in schizophrenia.
Function of 14q32 miRNA cluster in brain function and development The miR-379/410 cluster has been shown to follow a similar stage and tissue-specific expression pattern as a colocalized cluster of C/D snoRNAs derived from a single intronic transcript known as maternally expressed gene 8 (RNA imprinted and accumulated in the nucleus on mouse chromosome 12). 62 This is detectable throughout the developing mouse embryo and the placenta, is enriched in the brain in adult mice 29, 57, 62, 78 and may be significant for the development of higher brain functions in eutherian mammals. 79 The neural function of this cluster is supported by recent research suggesting that coordinated expression of these miRNA, including miR-134 and miR-329, is important for brain function and development. Neuronal activity in rats trigger MEF2, a neuronal-activity Ca 2 þ -dependent transcription factor (described above), to bind to sequence upstream of the larger of the two clusters and induce expression of all pre-miRNAs within it. 56 At least three members of the co-regulated cluster, including miR-329 and miR-134, that we see altered in schizophrenia, appear to regulate hippocampal neuron dendrite morphology. 56 MiR-134 has also been shown to repress dendritic development by targeting LimK1 28 and to activate it through targeting Pumilio2. 56 Interestingly, miR-134 expression is upregulated in the rat hippocampus and amygdala following acute stress, but is decreased during chronic stress. 60 A predicted target of miR-134, splicing factor SC35, has been shown to be upregulated after stress and is believed to promote alternative splicing of acetylcholinesterase mRNA. Therefore, it is possible that miR-134 and other related miRNAs from the 14q32 cluster function as stress-dependent regulators of neurotransmission and synaptic plasticity. This is supported by the pathway analysis of target genes predicted for differentially expressed miRNA in this cluster, which included axon guidance, regulation of the actin cytoskeleton, long-term potentiation, long-term depression, neuroactive ligand-receptor interaction, focal adhesion, neurotrophin, mammalian target of rapamycin, calcium, mitogen-activated protein kinase and ErbB signaling pathways. It was also broadly consistent with previous pathway analysis of the human 14q32 cluster and the syntenic miRNA c luster in the mouse, with enrichment of target genes involved in neurogenesis (including the biological processes in axon guidance), embryonic development and more general developmental processes. 79 Another interesting theme emerging from the pathway analysis was the large number of immunologically relevant processes including endocytosis, Fcg R-mediated phagocytosis, Fce RI signaling pathway, chemokine signaling pathway, T-cell receptor signaling pathway, leukocyte transendothelial migration and natural killer cell-mediated cytotoxicity. Given the evidence suggesting a link between early environmental exposure to infection/inflammation and schizophrenia, the alteration of miRNA expression in this tissue and their influence in these pathways could have functional significance for the immune system in individuals with the disorder. The expression of miRNA in this cluster was also shown to be highly associated with cellular pluripotency. 80 If this cluster is involved in the regulation and maintenance of stem cell behavior, the reduction observed in schizophrenia Imprinted DLK1-DIO3 miRNA signature in schizophrenia E Gardiner et al could have broad developmental implications for both the immune and nervous systems.
Differentially expressed miRNA are contained within an imprinted locus Maternal specific expression of this region is regulated by imprinting centers defined by an intergenic germline derived differentially methylated region (DMR) and the post-fertilization derived MEG3-DMR (shown in Figure 3) . 81 Differential expression of miRNA clustered in this imprinted region raises the possibility that there is a schizophrenia-associated parent of origin effect influencing the miRNA expression from this cluster similar to that observed at a number of other genes including the 5-hydroxytryptamine type 2A receptor 82 and GABA A receptor b2. 83 Imprinting at the 14q32 region has also been implicated in bipolar disorder 84, 85 and anxiety. 86 Although no gender bias was observed in the expression of the miRNA cluster, specific details about participants' parental disease status were not sufficient to derive parent of origin effect. Many characteristics of the imprinted locus on 14q32 parallel the genetic landscape at 15q11-13, known for its involvement in Prader-Willi Syndrome). This neurodevelopmental disorder arises from monoallelic expression at 15q11-13 as a result of deletion of the paternal copy of the imprinted region (delPWS), maternal uniparental disomy (mat-upd-15), as well as abnormal imprinting (reviewed by Buiting 87 ). The 14q32 and 15q11-13 regions are similar in that they are both developmentally regulated via an imprinting center, and contain both maternally and paternally expressed genes. The imprinted regions of both loci also encode C/D snoRNAs that function as guides for epigenetic modification of other RNAs. The snoRNAs in these loci are atypical in that they lack complementarity to their neighboring RNA. These small non-coding RNA molecules, exclusive to eutherians, are also brain enriched and transcribed in the same direction, possibly by a single transcription unit. 62, 64, [88] [89] [90] In further support of a role for these imprinted loci in neuronal development, Leung et al. 90 observed developmentally regulated chromatin decondensation of snoRNA clusters at 15q11-13 and 14q32 in postnatal mouse and human neurons.
Individuals with Prader-Willi Syndrome also share some phenotypic features with schizophrenia such as cognitive deficits, behavioral problems and, in some cases, autistic symptoms and psychosis. [91] [92] [93] [94] [95] [96] [97] The 14q32 locus has also been implicated in other disorders with impaired development and behavioral phenotypes. 98 Rare copy-number variations at 14q32 and 15q11-13 have also been reported in schizophrenia. [99] [100] [101] [102] Although our analysis of copy number in this region did not identify structural variants, this genomic region clearly has the potential to convey risk for neurodevelopmental disorders including schizophrenia.
Conclusions
In this study, we examined schizophrenia-associated miRNA expression and identified a significant correlation between miRNAs clustered in a small imprinted domain on 14q32. Although the cause of this anomaly is not known, it may be due to an alteration in transcriptional regulation or processing. The miRNAs encoded in this cluster evolved in eutherian mammals and appear to have a significant role in brain development and function. And while the significance of their downregulation in PBMCs in schizophrenia is less clear, there are implications for lymphocyte function that could contribute to the risk for the disorder. Alternatively, this phenomenon may be a vestige of broader alteration to post-transcriptional regulation, with more relevance to neurodevelopment. Regardless of the functional significance, the miRNA expression signatures observed in PBMCs may have the potential to serve as biomarkers of schizophrenia and associated phenotypes.
